MLTX · MoonLake Immunotherapeutics
$16.74
+0.40 (+2.45%)
At close · Aug 19
Market Cap
$1.39B
Shares
85.11M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$16.74
Open$16.57
Day$16.12–16.86
52W close$6.25–61.99
Avg vol 30d1.2M
Short int5.7M · 6.7% float · 6.6d
Short vol29%
Last earningsFeb 23, 2026
DataOct 2020–Aug 2026
Filing10-Q · Aug 10
Up next
Next earnings call
Aug 24, 2026
Est · unconfirmed
· in 1 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 10, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+0%
above
Price vs 50-day avg
−11%
below
RSI (14)
42
neutral
MACD trend
Negative
52-week position
19%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−12%
trailing
6-month return
−5%
trailing
YTD return
+27%
this year
Relative strength
−17%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $19 › 200d $17 — 50d above 200d
Institutional flow
Accumulating
+17% holders QoQ · +45 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
6.72% of float · ▼ -9.7% MoM · 6.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
174 holders — near 3-yr high, broad support
Squeeze score
66
elevated · 0–100
Fundamentals
EPS growth
−87%
Y/Y
Free cash flow
$-196.0M
Balance sheet
$260.4M
net cash
Quant / Vol
risk profile
Volatility
118%
annualized · 1-yr
Max drawdown
−90%
past year
ATR
5.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+0%
Bullish
Price vs 50-day avg
−11%
Bearish
RSI (14)
42
Neutral
MACD trend
Negative
Bearish
52-week position
19%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $19 › 200d $17 — 50d above 200d
Institutional flow
Accumulating
+17% holders QoQ · +45 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
6.72% of float · ▼ -9.7% MoM · 6.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
174 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $6
Now $17 · 19%
Range high $62
vs 200-day avg +0%
vs 50-day avg -11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MLTX
this stock
MoonLake Immunotherapeutics
|
$1.39B | +27.0% | — | — | 6.7% |
|
ONC
BeOne Medicines Ltd.
|
$535.83B | +24.0% | +22179.2% | 823.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.88B | +21.8% | +46.2% | 30.8 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.27B | +8.9% | +20.8% | 20.3 | 3.3% |
|
ARGX
Argenx SE
|
$61.75B | +22.8% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MLTX | -2.8% | -11.6% | -5.3% | -9.2% | +27.0% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | -2.4% | -14.5% | -16.9% | -12.2% | +14.2% |
Key facts
CIK
1821586
CUSIP
61559X104
13F (30d)
173 filings
167 filers
Visit website
Investor relations